SCHEMBL1347747

SCHEMBL1347747

NC(=O)c1cccc(-c2ccc(CNCCC3C4CC5CC(C4)CC3C5)cn2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 3/20 0.51
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
HPGDS O60760 2/20 0.40
PDCD1 Q15116 2/20 0.39
CD274 Q9NZQ7 2/20 0.39
FYN P06241 6/20 0.37
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
CCNT1 O60563 1/20 0.36
CCND1 P24385 1/20 0.36
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
CDK7 P50613 1/20 0.36
CDK9 P50750 1/20 0.36
CCNH P51946 1/20 0.36
MNAT1 P51948 1/20 0.36
CDK6 Q00534 1/20 0.36
FAAH O00519 1/20 0.36
PIK3CA P42336 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13929435 0.86 KDM1A (0.43) KDM1ACYP11B1CYP11B2HPGDSPDCD1
SCHEMBL1347869 0.86 KDM1A (0.46) KDM1ACYP11B1CYP11B2HPGDSPDCD1
SCHEMBL1347410 0.85 DHODH (0.42) KDM1AFYNMAOAMAOBCCNT1
SCHEMBL13929390 0.83 KDM1A (0.47) KDM1ACYP11B1CYP11B2HPGDSPDCD1
SCHEMBL1347739 0.82 KDM1A (0.48) KDM1ACYP11B1CYP11B2HPGDSPDCD1
SCHEMBL1345822 0.82 KDM1A (0.47) KDM1ACYP11B1CYP11B2HPGDSPDCD1
SCHEMBL1347678 0.82 KDM1A (0.47) KDM1ACYP11B1CYP11B2HPGDSPDCD1
SCHEMBL1346259 0.82 KDM1A (0.38) KDM1ACD274MAOAMAOBFAAH
SCHEMBL1347586 0.81 KDM1A (0.51) KDM1ACYP11B1CYP11B2HPGDSHDAC1
SCHEMBL1345704 0.80 KDM1A (0.46) KDM1ACYP11B1CYP11B2HPGDSPDCD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063247-B2 Bicyclic aryl and heteroaryl receptor modulators PROSIDION LIMITED (GB) 2011-11-22 US claimed
US-8063247-B2 Bicyclic aryl and heteroaryl receptor modulators PROSIDION LIMITED (GB) 2011-11-22 US disclosed
US-8063247-B2 Bicyclic aryl and heteroaryl receptor modulators PROSIDION LIMITED (GB) 2011-11-22 US disclosed
US-8063247-B2 Bicyclic aryl and heteroaryl receptor modulators PROSIDION LIMITED (GB) 2011-11-22 US disclosed
US-20100267780-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS PROSIDION LIMITED (GB) 2010-10-21 US disclosed
US-20100267780-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS PROSIDION LIMITED (GB) 2010-10-21 US disclosed
US-20100267780-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS PROSIDION LIMITED (GB) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267780-A1 BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS OPRM1, OPRL1, OPRD1 KDM1A 2408/4885CYP11B1 195/4885CYP11B2 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.